DE69939950D1 - Verwendung von neuregulin zur beeinflussung der herzmuskelfunktion - Google Patents

Verwendung von neuregulin zur beeinflussung der herzmuskelfunktion

Info

Publication number
DE69939950D1
DE69939950D1 DE69939950T DE69939950T DE69939950D1 DE 69939950 D1 DE69939950 D1 DE 69939950D1 DE 69939950 T DE69939950 T DE 69939950T DE 69939950 T DE69939950 T DE 69939950T DE 69939950 D1 DE69939950 D1 DE 69939950D1
Authority
DE
Germany
Prior art keywords
neuregulin
cardiomyocyte
influence
muscular function
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939950T
Other languages
English (en)
Inventor
Mingdong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Application granted granted Critical
Publication of DE69939950D1 publication Critical patent/DE69939950D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
DE69939950T 1998-12-21 1999-12-21 Verwendung von neuregulin zur beeinflussung der herzmuskelfunktion Expired - Lifetime DE69939950D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP7850A AUPP785098A0 (en) 1998-12-21 1998-12-21 Treatment of heart disease
PCT/AU1999/001137 WO2000037095A1 (en) 1998-12-21 1999-12-21 Cardiac muscle function and manipulation

Publications (1)

Publication Number Publication Date
DE69939950D1 true DE69939950D1 (de) 2009-12-10

Family

ID=3812054

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939950T Expired - Lifetime DE69939950D1 (de) 1998-12-21 1999-12-21 Verwendung von neuregulin zur beeinflussung der herzmuskelfunktion

Country Status (7)

Country Link
US (6) US7226907B1 (de)
EP (3) EP2027869B1 (de)
AT (1) ATE442156T1 (de)
AU (2) AUPP785098A0 (de)
DE (1) DE69939950D1 (de)
ES (2) ES2318909T3 (de)
WO (1) WO2000037095A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
WO2003025205A2 (en) * 2001-09-19 2003-03-27 Medigene Ag Extracellular regulated kinase 2 (erk2)
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DE602006017071D1 (de) 2005-01-25 2010-11-04 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
AU2013203483B2 (en) * 2005-12-30 2015-11-05 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
US8936806B2 (en) * 2007-01-22 2015-01-20 Children's Medical Center Corporation Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP2808339B1 (de) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin-Peptide und deren Verwendung
JP2012509908A (ja) * 2008-11-28 2012-04-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
JP2013503110A (ja) 2009-06-09 2013-01-31 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンに基づく心不全の治療方法
ES2575125T3 (es) * 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
US20120121557A1 (en) * 2009-07-22 2012-05-17 Children's Medical Center Corporation Neuregulin induced proliferation of cardiomyocytes
CA2769030C (en) 2009-07-30 2016-05-10 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
US20120253102A1 (en) * 2009-10-27 2012-10-04 Cedars-Sinai Medical Center External magnetic force for targeted cell delivery with enhanced cell retention
CN103772498B (zh) * 2009-11-09 2015-07-15 上海泽生科技开发有限公司 纽兰格林及其用途
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
CN103124788B (zh) 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
US9168297B2 (en) * 2010-06-23 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (NRG-1)
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
EP2861238A4 (de) 2012-06-05 2016-03-16 Capricor Inc Optimierte verfahren zur erzeugung von herzstammzellen aus herzgewebe und deren verwendung in der herztherapie
US8791067B2 (en) 2012-07-24 2014-07-29 Morehouse School Of Medicine Method for treating malaria
WO2014018018A1 (en) * 2012-07-24 2014-01-30 Morehouse School Of Medicine Composition and method for reducing tissue damage from inflammatory disorder or pathogenic infection
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
AU2012392119B2 (en) * 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
AU2014270882B2 (en) 2013-05-22 2019-03-14 Zensun (Shanghai) Science & Technology, Co. Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3353546A1 (de) * 2015-09-25 2018-08-01 Douglas B. Sawyer Verfahren zur behandlung von herzverletzungen
JP7005019B2 (ja) 2015-10-02 2022-02-04 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッド 組織修復のための二重特異性治療用タンパク質
EP3402543B1 (de) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Aus kardiosphäre stammende zellen und durch solche zellen sekretierte exosomen in der behandlung von herzversagen mit konservierter auswurffraktion
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (de) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center Kardiosphärenzellen und deren extrazelluläre vesikel zur verzögerung oder umkehr des alterungsprozesses und altersbedingten erkrankungen
EP3612191A4 (de) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
SG11202009831UA (en) * 2018-04-11 2020-11-27 Salubris Biotherapeutics Inc Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
JP2022547335A (ja) 2019-09-16 2022-11-11 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 組換えヒトニューレグリン誘導体及びその使用
CN113289002A (zh) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
WO2022261299A1 (en) 2021-06-10 2022-12-15 Amgen Inc. Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (de) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
JPH02226533A (ja) 1989-02-27 1990-09-10 Mitsubishi Electric Corp 情報記録媒体
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
GB9107566D0 (en) 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
NO942396L (no) 1993-06-24 1994-12-27 Takeda Chemical Industries Ltd Preparat med vedvarende frigiving av anti-endotelin substans
US5770567A (en) 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
AUPM959894A0 (en) * 1994-11-22 1994-12-15 Crc For Biopharmaceutical Research Pty Ltd Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
AU712585B2 (en) 1995-03-10 1999-11-11 Genentech Inc. Receptor activation by gas6
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5721139A (en) 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US5714385A (en) 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US6033660A (en) 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2000502682A (ja) * 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
JP4382879B2 (ja) 1996-07-12 2009-12-16 ジェネンテック・インコーポレーテッド ガンマ―ヘレグリン
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6136558A (en) 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
CA2278151C (en) 1997-02-10 2010-11-16 Genentech, Inc. Heregulin variants
US6162641A (en) * 1997-06-06 2000-12-19 The Regents Of The University Of Michigan Neuregulin response element and uses therefor
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
TW379182B (en) * 1997-07-23 2000-01-11 Matsushita Electric Ind Co Ltd Packing materials for small parts, packing method and packing apparatus as well as the packing method for electronic parts
WO1999018976A1 (en) * 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6446242B1 (en) * 1999-04-02 2002-09-03 Actel Corporation Method and apparatus for storing a validation number in a field-programmable gate array
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
CN1743006A (zh) 2004-09-02 2006-03-08 上海泽生科技开发有限公司 Mapk抑制剂的新用途及组合物
CN1743005A (zh) 2004-09-02 2006-03-08 上海泽生科技开发有限公司 Pi3－k抑制剂的新用途及组合物
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
JP2012509908A (ja) * 2008-11-28 2012-04-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
EP2808339B1 (de) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin-Peptide und deren Verwendung
JP2013503110A (ja) * 2009-06-09 2013-01-31 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンに基づく心不全の治療方法

Also Published As

Publication number Publication date
US7964555B2 (en) 2011-06-21
AUPP785098A0 (en) 1999-01-21
ATE442156T1 (de) 2009-09-15
EP2027869B1 (de) 2012-08-08
EP1158998B1 (de) 2009-09-09
US7226907B1 (en) 2007-06-05
EP2027869A3 (de) 2009-03-04
US20070264254A1 (en) 2007-11-15
EP2027869A2 (de) 2009-02-25
ES2392596T3 (es) 2012-12-12
AU2422400A (en) 2000-07-12
US20170189489A1 (en) 2017-07-06
ES2318909T3 (es) 2009-11-24
US20060194734A1 (en) 2006-08-31
US20060199767A1 (en) 2006-09-07
WO2000037095A1 (en) 2000-06-29
EP1158998A4 (de) 2002-06-05
EP2351573A1 (de) 2011-08-03
US20070129296A1 (en) 2007-06-07
EP1158998A1 (de) 2001-12-05
US7612164B2 (en) 2009-11-03

Similar Documents

Publication Publication Date Title
DE69939950D1 (de) Verwendung von neuregulin zur beeinflussung der herzmuskelfunktion
DE68908044T2 (de) Hilfsmittel zur Verwendung mit Pflanzenschutzmitteln.
DE58906718D1 (de) Kunststeine, verfahren zur herstellung und verwendung derselben.
DE69016426D1 (de) Biologische klappenprothese.
DE3877174D1 (de) Bezugssystem zur implantation von kondylaeren knie-totalprothesen.
DE3879928D1 (de) Prothetische vorrichtung zur erhoehung der nachgiebigkeit von arterien.
DE3788584D1 (de) Sulfonylharnstoff-Verbindungen, ihre Herstellung und Verwendung als Herbizide.
DE68916653D1 (de) Methode zur herstellung von lichtwellenleiterreihen.
DE69017806D1 (de) Methode der Identifizierung einer Information und Informationsträger zur Verwendung mit dieser Methode.
DE3886672D1 (de) Technik zur Verwendung bei der Herstellung von Halbleiteranordnungen mit submikrometrischen Merkmalen.
DE3868910D1 (de) Implantat zur befestigung von zahnprothesen.
DE238479T1 (de) Klappbares optisches teil zur verwendung mit brillen.
DE68913991T2 (de) Implantat zur verwendung in der knochenchirurgie.
DE3777020D1 (de) Stopfen zur verwendung in bohrloechern.
DE68916266D1 (de) Methode zur Herstellung und Stabilisierung von Halosilanen mit Acrylfunktionen.
DE3878375D1 (de) Proportionalventil zur verwendung bei blockierverhinderern.
DE3870764D1 (de) Anilinophenylthioharnstoffe, -isothioharnstoffe und -carbodiimide, ihre herstellung und verwendung in der schaedlingsbekaempfung.
DE3872160T2 (de) Morpholinylsilane und verwendung zur beherrschung von pflanzenkrankheiten, verursacht durch pilze.
DE3868665D1 (de) Nichtausfransendes substrat zur verwendung bei orthopaedischen bandagen und verfahren zu seiner herstellung.
DE58904049D1 (de) Cyclopropancarboxamide, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen.
DE59105568D1 (de) Alpha-Arylacrylsäurederivate, ihre Herstellung und Verwendung zur Bekämpfung von Schädlingen und Pilzen.
DE59711586D1 (de) Vorrichtung zur Steuerung eines Herzstimulators aufgrund der Blutsauerstoffsättigung
ATA148888A (de) Streumittel zur bodenverbesserung mit huminsaeure, kieselsaeure und wuchsstoffen auf poroesem traeger
PT86606A (pt) Bakterienlysierendes enzymprodukt aus streptomyceten seine herstellung und seine verwendung zur konservierung von kaese
DE59104129D1 (de) 2,2'-Thienyl-benzothiophene, ihre Herstellung und ihre Verwendung zur Bekämpfung von Schädlingen.

Legal Events

Date Code Title Description
8372 Publication of ep patent withdrawn
8364 No opposition during term of opposition